<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887925</url>
  </required_header>
  <id_info>
    <org_study_id>BreastCaCTx_circadian</org_study_id>
    <nct_id>NCT01887925</nct_id>
  </id_info>
  <brief_title>The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy</brief_title>
  <official_title>The Effects of Per3, Clock Polymorphism on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of effect of circadian gene on sleep and other
      symptoms in breast cancer patients under chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to examine the effect of genetic polymorphism on
      sleep, anxiety, depression and other cancer-related symptoms in patients with breast cancer
      who have started chemotherapy after surgery. No intervention was intended and blood sample
      was taken with other routine laboratory tests.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes from Baseline Sleep Impairment at 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep impairment will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Quality of Life at 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Cancer-related Symptoms at 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cancer-related symptoms will be evaluated by questionnaires before chemotherapy.
The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Fatigue at 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fatigue will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Depression at 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depression will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Anxiety 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anxiety will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline PTSD Symptoms 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>PTSD symptoms will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline Menopausal Symptoms 1 Month After Chemotherapy</measure>
    <time_frame>baseline, 1 month, 3 months, 1 month after chemotherpy completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Menopausal symptoms will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>breast cancer</arm_group_label>
    <description>breast cancer patients receiving chemotherapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        university hospital, oncology clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70

          -  Patient with breast cancer without metastasis

          -  Patient received cancer surgery and medically stable

          -  Patient will undergo chemotherapy for the first time in life

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study

        Exclusion Criteria:

          -  Patient received chemotherapy or radiotherapy

          -  Patient had another cancer before

          -  Patient have metastasis

          -  Patient with severe medical condition

          -  Patient had taken psychiatric medication more than 1 month in life

          -  Patient worked the night shift for more than 1 month in 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dooyoung Jung</last_name>
    <phone>82220723767</phone>
    <email>dooyoung@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>140-013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dooyoung Jung, MD</last_name>
      <phone>82220723767</phone>
      <email>dooyoung@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bong-Jin Hahm, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dooyoung Jung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.snuh.org/</url>
    <description>study site</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bong-Jin Hahm</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>breast neoplasms</keyword>
  <keyword>sleep</keyword>
  <keyword>anxiety</keyword>
  <keyword>depression</keyword>
  <keyword>life quality</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
